Moderna (MRNA) Free Cash Flow (2018 - 2026)

Moderna (MRNA) has 9 years of Free Cash Flow data on file, last reported at -$665.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 42.37% year-over-year to -$665.0 million in Q1 2026; TTM through Mar 2026 was -$1.6 billion, a 48.66% increase from a year earlier, with the FY2025 full-year figure at -$2.1 billion, up 33.41% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$665.0 million, down from $891.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for MRNA reached as high as $2.7 billion in Q1 2022 and fell as low as -$1.6 billion in Q3 2023.
• Historically, Free Cash Flow has averaged -$298.5 million across 5 years, with a median of -$849.0 million in 2025.
• Across the five-year window, Free Cash Flow slumped 1107.98% in 2023 and surged 1179.37% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at $1.6 billion in 2022, then plunged by 95.99% to $63.0 million in 2023, then jumped by 1179.37% to $806.0 million in 2024, then grew by 10.55% to $891.0 million in 2025, then tumbled by 174.64% to -$665.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$665.0 million in Q1 2026, $891.0 million in Q4 2025, and -$953.0 million in Q3 2025.